Business Context and Reporting Period
This Form 8-K Current Report is filed by Senti Biosciences Holdings, Inc. (SNTI) on August 27, 2026. The filing addresses two primary events: the amendment of a material definitive agreement regarding senior secured convertible notes and the receipt of notices from The Nasdaq Stock Market LLC regarding non-compliance with listing standards.
Key Financial Metrics and Liquidity
- Stockholders' Deficit: The company reported a stockholders' deficit of $3,401,000 as of June 30, 2026.
- Debt Financing: An amendment to the Securities Purchase Agreement authorizes the issuance of $2.0 million in aggregate principal of Senior Secured Convertible Notes to NSG BioInnovation Fund, L.P. in a third tranche.
- Stock Price: The closing bid price of the common stock has been below the $1.00 minimum requirement for 30 consecutive trading days as of August 27, 2026.
- Revenue and Profit: The filing text does not provide specific values for revenue, profit, or cash flow for the current period.
Material Changes and Listing Status
The company is currently non-compliant with two Nasdaq Capital Market listing rules:
- Minimum Bid Price Requirement: Failed to maintain a closing bid price of at least $1.00 per share for 30 consecutive trading days.
- Stockholders' Equity Requirement: Failed to maintain minimum stockholders' equity of $2.5 million due to the reported deficit.
Neither notice has an immediate effect on the trading of the common stock, which continues to trade under the symbol "SNTI."
Compliance Deadlines and Plans
- Bid Price Compliance: The company has an initial 180-day period (until February 23, 2027) to regain compliance. The stock must close at or above $1.00 for 10 consecutive trading days. The company may effect a reverse stock split if necessary.
- Equity Compliance: The company must submit a plan to regain compliance to Nasdaq by October 11, 2026. If accepted, an extension of up to 180 days may be granted.
Outlook, Risks, and Contingencies
Management Commentary and Strategy: Management intends to monitor the stock price and may pursue a reverse stock split, subject to Board and stockholder approval. A preliminary proxy statement regarding a reverse stock split has been filed in connection with the 2026 Annual Meeting.
Subject Transactions: The filing references potential transactions involving a merger with an entity affiliated with Celadon Partners and the issuance of contingent value rights. These rights could pay out up to $60.0 million in cash if certain regulatory and sales milestones for the product candidate SENTI-202 are achieved.
Risks: There is no assurance the company will regain compliance with Nasdaq listing rules. Failure to do so could result in delisting. Additionally, the success of the Subject Transactions and the contingent value rights is subject to achieving specific milestones.
Investor Verification Checklist
- Verify the status of the $2.0 million note issuance to NSG BioInnovation Fund, L.P. and the closing conditions.
- Monitor the company's stock price to determine if it meets the $1.00 threshold for 10 consecutive days before February 23, 2027.
- Review the definitive proxy statement regarding the proposed reverse stock split and the Subject Transactions (merger and contingent value rights).
- Confirm the submission and acceptance of the plan to regain stockholders' equity compliance by the October 11, 2026 deadline.
- Assess the likelihood of achieving the regulatory and sales milestones required for the potential $60.0 million contingent value right payout.